An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00082617" target="_blank" >RIV/00023001:_____/22:00082617 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10434186

Výsledek na webu

<a href="https://www.tandfonline.com/doi/abs/10.1080/14740338.2021.1978974?journalCode=ieds20" target="_blank" >https://www.tandfonline.com/doi/abs/10.1080/14740338.2021.1978974?journalCode=ieds20</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14740338.2021.1978974" target="_blank" >10.1080/14740338.2021.1978974</a>

Jazyk výsledku

angličtina

Název v původním jazyce

An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

Popis výsledku v původním jazyce

Introduction Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. Areas covered There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. Expert opinion FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.

Název v anglickém jazyce

An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

Popis výsledku anglicky

Introduction Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. Areas covered There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. Expert opinion FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert opinion on drug safety

ISSN

1474-0338

e-ISSN

1744-764X

Svazek periodika

21

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

13

Strana od-do

349-361

Kód UT WoS článku

000707132600001

EID výsledku v databázi Scopus

2-s2.0-85117219525